Wells Fargo & Company Biond Vax Pharmaceuticals Ltd. Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.48 - $2.92 $210 - $414	-142 Reduced 41.52%	200 $0
Q2 2021 Aug 16, 2021	SELL	$2.6 - $3.91 $1,471 - $2,213	-566 Reduced 62.33%	342 $1,000
Q1 2021 May 13, 2021	SELL	$3.1 - $5.95 $2,452 - $4,706	-791 Reduced 46.56%	908 $3,000
Q4 2020 Feb 09, 2021	SELL	$2.5 - $40.97 $5,160 - $84,562	-2,064 Reduced 54.85%	1,699 $5,000
Q3 2020 Nov 05, 2020	BUY	$23.7 - $51.1 $61,359 - $132,297	2,589 Added 220.53%	3,763 $147,000
Q2 2020 Aug 13, 2020	BUY	$7.2 - $24.87 $2,160 - $7,461	300 Added 34.32%	1,174 $27,000
Q1 2020 May 14, 2020	BUY	$5.36 - $11.65 $4,684 - $10,182	874 New	874 $7,000

Ticker BVXV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,678,800
Market Cap $12M
Description
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Götting...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.